NYSEAMERICAN:PHGE BiomX Q1 2026 Earnings Report $1.85 0.00 (0.00%) As of 09/10/2026 ProfileEarnings HistoryForecast BiomX EPS ResultsActual EPS$73.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABiomX Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABiomX Announcement DetailsQuarterQ1 2026Date5/20/2026TimeBefore Market OpensConference Call DateWednesday, May 20, 2026Conference Call Time4:00PM ETUpcoming EarningsBiomX's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) BiomX Earnings HeadlinesBiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Up 83.3% in AugustSeptember 18 at 4:21 AM | americanbankingnews.comTessera Defense and Homeland Security CEO Issues Letter to ShareholdersSeptember 15, 2026 | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 21 at 1:00 AM | Chaikin Analytics (Ad)Tessera Begins Trading Under HLSQ as Demand Grows for Connected Physical SecuritySeptember 11, 2026 | finance.yahoo.comBiomX Announces Reverse Stock Split and Rebranding PlanSeptember 9, 2026 | tipranks.comBiomX: Zorronet Launches No-Code Control Over AI-Powered Autonomous Response WorkflowsSeptember 4, 2026 | globenewswire.comSee More BiomX Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BiomX? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BiomX and other key companies, straight to your email. Email Address About BiomXBiomX (NYSEAMERICAN:PHGE) is a clinical-stage biotechnology company developing precision therapies that target harmful bacteria while seeking to preserve beneficial components of the microbiome. The company’s platform uses bacteriophages, naturally occurring viruses that selectively infect and destroy specific bacterial strains, to address diseases associated with bacterial imbalances or persistent infections. BiomX’s development programs have included BX004, an inhaled phage therapy designed to target Pseudomonas aeruginosa infections associated with cystic fibrosis, and BX211, a candidate intended to target bacteria implicated in ulcerative colitis. The company has also worked on phage-based approaches for other chronic and infectious diseases, including programs focused on identifying and eliminating disease-associated bacterial strains. BiomX was founded in Israel and has conducted research and clinical development activities in Israel, the United States and other international locations. The company’s operations have been supported by collaborations with academic and clinical institutions as it advances its microbiome-focused therapeutics. Jonathan Solomon has served as chief executive officer and has been associated with the company’s development of targeted bacteriophage treatments.View BiomX ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to GrowthThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big Move Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
